Symptom prevalence in lung and colorectal cancer patients
- PMID: 24973624
- PMCID: PMC4277493
- DOI: 10.1016/j.jpainsymman.2014.06.003
Symptom prevalence in lung and colorectal cancer patients
Abstract
Context: Relatively few data are available about symptoms among cancer patients.
Objectives: To describe the prevalence and severity of symptoms among a large, representative cohort of newly diagnosed cancer patients.
Methods: We collected survey data about symptoms (pain, fatigue, depression, nausea/vomiting, cough, dyspnea, and diarrhea) from 5422 patients with incident lung and colorectal cancer from the diverse, nationally representative Cancer Care Outcomes Research and Surveillance Consortium cohort. We described the prevalence of any symptoms and moderate/severe symptoms approximately four to six months after diagnosis. We used logistic regression to identify patient and clinical characteristics associated with symptoms, and calculated adjusted proportions of patients with symptoms.
Results: In total, 5067 (93.5%) patients reported at least one symptom in the four weeks before their survey, with 51% reporting at least one moderate/severe symptom. Lung cancer patients reported more symptoms than colorectal cancer patients. Patients who received treatment or had more comorbidities were more likely to report symptoms. For example, after adjustment, patients who received chemotherapy during the six weeks before the survey were more likely than others to report at least one symptom (97.3% vs. 90.8%, P<0.001), and at least one moderate/severe symptom (56.8% vs. 46.2%, P<0.001). After adjustment, early- vs. late-stage patients did not differ in reports of at least one symptom (93.6% vs. 93.4%, P=0.853) and differed only slightly in reports of at least one moderate/severe symptom (53.3% vs. 49.6%, P=0.009).
Conclusion: Most recently diagnosed lung and colorectal cancer patients have cancer-related symptoms regardless of stage, and more than half have at least one moderate/severe symptom.
Keywords: Cancer; colorectal neoplasms; lung neoplasms; prevalence; symptoms.
Published by Elsevier Inc.
Conflict of interest statement
Drs. Walling, Kahn, Tisnado, Keating, Dy, Arora, and Mack and Mr. Pantoja have no conflicts of interest to disclose. Dr. Malin is currently employed at Wellpoint, Inc. and has stock ownership in same.
Figures
References
-
- Arora NK. Importance of patient-centered care in enhancing well-being from a cancer survivor’s perspective. Qual Life Res. 2009;18:1–4. - PubMed
-
- Teunissen SC, Wesker W, Kruitwagen C, et al. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage. 2007;34:94–104. - PubMed
-
- Agency for Healthcare Research and Quality. Evidence report/Technology assessment. 61. Rockville, MD: U.S. Department of Health and Human Services; 2002. Management of cancer symptoms: pain, depression, and fatigue.
-
- Liao Y, Liao W, Shun S, et al. Symptoms, psychological distress, and supportive care needs in lung cancer patients. Support Car Cancer. 2011;19:1743–1751. - PubMed
Publication types
MeSH terms
Grants and funding
- U01 CA093329/CA/NCI NIH HHS/United States
- U01 CA093348/CA/NCI NIH HHS/United States
- U01 CA093324/CA/NCI NIH HHS/United States
- R01 CA164021/CA/NCI NIH HHS/United States
- UL1TR000123/TR/NCATS NIH HHS/United States
- UL1 TR000124/TR/NCATS NIH HHS/United States
- U01 CA093339/CA/NCI NIH HHS/United States
- U01 CA093344/CA/NCI NIH HHS/United States
- U54 TR000123/TR/NCATS NIH HHS/United States
- U01 CA093332/CA/NCI NIH HHS/United States
- L30 AG030993/AG/NIA NIH HHS/United States
- U01 CA093326/CA/NCI NIH HHS/United States
- R011CA164021-01A1/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical